Defining hip osteoarthritis feature prevalence, severity, and change using the Scoring of Hip Osteoarthritis with MRI (SHOMRI)
Skeletal Radiology · 2024
DOI: 10.1007/s00256-024-04628-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Skeletal Radiology, 2024. Verfasst von Joshua J Heerey und 7 weiteren Autor:innen. Beteiligte Einrichtung: La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Bundoora, Australia. j.…. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Osteoarthritis, Hip, Severity of Illness Index. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, La Trobe University.
Abstract (Originalsprache)
Objective
To define the reporting of Scoring Hip Osteoarthritis with MRI (SHOMRI) feature prevalence and severity, and to develop criteria to monitor feature change in longitudinal investigations.
Methods
Twenty-five participants (50 hips) of the femoroacetabular impingement and hip osteoarthritis cohort study underwent baseline and 2-year follow-up 3 T hip MRIs. Eight hip OA features were assessed using the SHOMRI. All MRIs were read paired with knowledge of timepoint by two blinded musculoskeletal radiologists. We provide definitions to report SHOMRI feature prevalence, severity, and longitudinal change.
Results
We report clear definitions for SHOMRI feature prevalence, severity, and change. When we applied the definitions to the studied cohort, we could detect the prevalence, severity, and change of hip OA features. For example, 88% of hips had labral tears (34% graded as severe tears) and 76% had cartilage defects (42% graded as full thickness). Over 70% of hips had feature change over 2 years, highlighting the sensitivity of SHOMRI definitions to assess longitudinal change of hip OA features. Intra-reader reliability was almost perfect (weighted (w)-kappa 0.86 to 1.00), with inter-reader reliability substantial to almost perfect (w-kappa 0.80 to 1.00).
Conclusion
This study is the first to provide definitions to report SHOMRI feature prevalence, severity, and change. The proposed definitions will enable comparison between hip MRI studies and improve our understanding of hip OA pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Bundoora, Australia. j.heerey@latrobe.edu.au.
- Department of Radiology and Biomedical Imaging, University of California-San Francisco, San Francisco, CA, USA.
- Department of Physical Therapy and Rehabilitation Science, University of California-San Francisco, San Francisco, CA, USA.
- La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Bundoora, Australia.
Förderung
- National Health and Medical Research Council
- La Trobe University
Zitieren
APA
Heerey, J. J., Souza, R. B., Link, T. M., Luitjens, J., Gassert, F., Kemp, J. L., Scholes, M. J., & Crossley, K. M. (2024). Defining hip osteoarthritis feature prevalence, severity, and change using the Scoring of Hip Osteoarthritis with MRI (SHOMRI). Skeletal Radiology. https://doi.org/10.1007/s00256-024-04628-0
Vancouver
Heerey JJ, Souza RB, Link TM, Luitjens J, Gassert F, Kemp JL, et al. Defining hip osteoarthritis feature prevalence, severity, and change using the Scoring of Hip Osteoarthritis with MRI (SHOMRI). Skeletal Radiology. 2024. doi:10.1007/s00256-024-04628-0
BibTeX
@article{Heerey2024,
author = {Heerey, Joshua J and Souza, Richard B and Link, Thomas M and Luitjens, Johanna and Gassert, Felix and Kemp, Joanne L and Scholes, Mark J and Crossley, Kay M},
title = {Defining hip osteoarthritis feature prevalence, severity, and change using the Scoring of Hip Osteoarthritis with MRI (SHOMRI)},
journal = {Skeletal Radiology},
year = {2024},
doi = {10.1007/s00256-024-04628-0}
}
EUVIMED